Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) plus abiraterone acetate plus prednisone (AA plus P) plus leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa).